1. T-Cell Clonality; T cell antigen receptors, Gene Rearrangement; Laboratory

2. Here we review the conceptual foundations of T cell Clonality assays, including T cell ontogeny and T cell receptor …

3. Here we review the conceptual foundations of T cell Clonality assays, including T cell ontogeny and T cell receptor structure and function; we also provide an introduction to T cell receptor genomics and the concept of the T cell clonotype.

4. We conclude that skeletal muscle Antagonizes T cell exhaustion by protecting T cell proliferative potential from inflammation and replenishing the effector T cell progeny pool in lymphoid organs.

5. CD4+ T-cell absolute counts was 1.5 times higher than the percent C.V. for CD4+ T-cell percentages.

6. Chimeric Antigen Receptor (CAR) T-cell Therapy

7. We propose that the TCF1-Bcl6 axis Counteracts type I interferon to repress T cell exhaustion and maintain T cell stemness, which is critical for persistent antiviral CD8 T cell responses in chronic infection.

8. Thymic stromal cell cultures for t-cell differentiation

9. T cell Clonality testing has important clinical and research value, providing a specific and reproducible assessment of clonal diversity in T cell proliferations

10. T cell Clonality testing has important clinical and research value, providing a specific and reproducible assessment of clonal diversity in T cell proliferations

11. Costimulatory molecules are key elements in T cell activation.

12. Cutaneous T-cell lymphoma is a type of cancer

13. T cell Clonality testing has important clinical and research value

14. Upon contact with its specific antigen, the T cell receptor transduces an activation signal into the T cell, leading to proliferation, cytokine production, or efficient cytotoxicity.

15. Clinical and experimental data suggest impairment of T-cell functions.

16. Novel peptide for inhibiting t cell activity and use thereof

17. A Cytotoxic T cell releases toxic substances that kill infected cells.

18. Normalization of defective t cell responsiveness through manipulation of thymic regeneration

19. Immunocytologic studies revealed the T-cell origin of these thymic type lymphomas.

20. An animal model and method of treatment for human t cell leukemia

21. Cutaneous T-cell lymphoma (CTCL) is a general term for several types of T-cell lymphomas of the skin, including mycosis fungoides, Sézary syndrome, primary Cutaneous anaplastic large cell lymphoma, lymphomatoid papulosis, granulomatous slack skin disease, pagetoid reticulosis, and subCutaneous panniculitis-like T-cell lymphoma, to name a few.

22. Allo- and auto-reactive t-cell epitopes from rhesus protein and their use

23. As with B cells, each type of T cell recognizes a different antigen.

24. Antibiotic exposure Accelerates diabetes in NOD mice and alters CD4+ T-cell populations

25. T-cell kinetics, activation and cytokine production are highly sensitive to nasal steroids.

26. These cells are characterized by high endocytic activity and low T-cell activation potential.

27. As part of the standard T cell Clonality assay, most laboratories rely on the demonstration of electrophoretic migration patterns for the determination of Clonality: a prototypical ‘polyclonal’ T cell population will produce an electropherogram with a Gaussian distribution of low-fraction amplicon peaks; in contrast, a bona fide ‘monoclonal’ T cell population will produce an electropherogram with a …

28. Haematology See Plasminogen Activation Immunology See Complement Activation, Lymphocyte Activation, Macrophage Activation, T cell Activation

29. Drug containing antibodies for treatment of t cell specific immune reactions and t cells leukemias

30. Such Bulged pMHC-I complexes represent challenges for T-cell receptor (TCR) ligation, although t …

31. 24 Objective To study the relationship of Epstein Barr virus ( EBV ) and T cell lymphoma.

32. Models of T cell Anergy affecting both CD4(+) and CD8(+) cells fall into two broad cate …

33. Adaptive immune responses to AAV Capsid usually result in neutralizing antibody responses and T-cell responses

34. Glycolysis and glutaminolysis Cooperatively control T cell function by limiting metabolite supply to N-glycosylation Elife

35. The company is involved in developing a pipeline of multiple Allogeneic T cell product candidates utilizing

36. Here, we review the functional abnormalities and the contribution of different T-cell subsets to rheumatoid inflammation.

37. The T-cell stimulator will slow down the rate of change but until I find the cause...

38. The Clonality and T‐cell fraction were log2 transformed to correct for the skewness of the data

39. Achilles pipeline Our lead product is a personalised tumour-derived T cell therapy targeting clonal cancer neoantigens

40. Neuroinvasive West Nile Infection Elicits Elevated and Atypically Polarized T Cell Responses That Promote a Pathogenic Outcome.

41. Preventives or remedies for sensitized t cell-related diseases containing il-6 antagonists as the active ingredient

42. Adoptive T-cell therapies with T-cells modified with chimeric antigen receptors (CAR-T) also causes CRS.

43. The Arnt-STAT3 axis is a critical regulator of TCRalphabeta CD8alphaalpha intestinal intraepithelial T-cell development and differentiation.

44. Clonal expansion was analyzed by quantifying similar T cell clones on the basis of the TCR sequence information

45. Establishment of a GAT-specific suppressor T cell clone from GAT-tolerant responders which Afferently regulates DTH responses

46. The invention provides a method for modulating CD4 T cell function by administration of antibodies to CD-40.

47. Absorption of anti-brain serum with liver and plasmocytoma cells led to residual specific anti T-cell activity.

48. The relationship between acral ischemia and T-cell-lymphoma is not clear but is discussed in this article.

49. The AVN composed of four types cells, P cell, T cell, Purkinje cell and normal cardiac working cell.

50. This displaces the antigenic peptide away from the TCR and circumvents the normal mechanism for T-cell activation.

51. Allogene Therapeutics is a clinical-stage biotechnology company pioneering the development of Allogeneic chimeric antigen receptor T cell

52. B-cell Prolymphocytic Leukemia (T-PLL) is a mature post-thymic T-cell malignancy with aggressive clinical course.

53. Propanc Biopharma Analyzes Pancreatic Proenzymes Vs T-Cell Therapy Targeting Solid Tumors Such as Pancreatic, Ovarian & Colorectal Cancers

54. Cutaneous T-cell lymphoma (CTCL) is the most common type of Cutaneous lymphoma, representing about 80 percent of cases

55. Operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered Allogeneic T cell …

56. The Company develops Allogeneic chimeric antigen receptor T-cell therapy for the treatment of blood cancers and solid tumors.

57. Through production of these cytokines, iNKT cells control adipose Treg and other T cell survival, proliferation and suppressor functions.

58. Working in tandem, RAG-1 and RAG-2 pour out the millions of antibodies and T-cell receptors needed.

59. Oncofetal gene SALL4 reactivation by hepatitis B virus Counteracts miR-200c in PD-L1-induced T cell exhaustion Nat Commun

60. The company is involved in developing a pipeline of multiple Allogeneic T cell product candidates utilizing validated gene editing and

61. Consistent with these findings, induction of SHIP deficiency prior to receiving a T cell replete BM graft abrogates acute GVHD.

62. T-cell acute lymphoblastic leukaemia (T-ALL) is an aggressive haematologic cancer associated with a high white blood cell count.

63. CD8+ (Cytotoxic) T cells, like CD4+ Helper T cells, are generated in the thymus and express the T-cell receptor

64. Cutaneous T-cell lymphomas (CTCL) are caused by the uncontrolled division of abnormal T-cells that have accumulated in the skin

65. --Cabaletta Bio, Inc., a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients …

66. Additionally, SIT causes an inhibition of the T cell response by induction of anergy and immuno-regulation leading to immunological tolerance.

67. It is mainly engaged in the development and commercialization of genetically engineered Allogeneic T cell therapies for the treatment of cancer

68. It is mainly engaged in the development and commercialization of genetically engineered Allogeneic T cell therapies for the treatment of cancer

69. Objective:To detect the clinicopathologic features of nasal NK/T-cell lymphoma in Guangxi and their association with Epstein-Barr virus (EBV).

70. Operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered Allogeneic T cell therapies for the

71. Principally different are inhibitors of complement convertases or collagenase as well as vaccination studies or trials trying to induce T cell anergy.

72. 8 Objective:To detect the clinicopathologic features of nasal NK/T-cell lymphoma in Guangxi and their association with Epstein-Barr virus (EBV).

73. The APC then travels to a lymph node, where it presents the displayed allergen to a CD4+ T-cell, or T-helper cell.

74. A significant correlation was observed between lower donor T cell Chimerism at 1 year and CMV reactivation or EBV viremia early after HSCT.

75. A Th 1/T helper 2 imbalance characterizes T-cell responses in active drinkers with ARC, whereas IL-4 production prevails in Abstinents

76. An Antigen-specific B cell antibody specifically recognizes a TI-2 Antigen, but without T cell help, a memory response is not seen.

77. Infusion of Human Bone Marrow-Derived Mesenchymal Stem Cells Alleviates Autoimmune Nephritis in a Lupus Model by Suppressing Follicular Helper T-Cell Development

78. Allogene Therapeutics has linked its off-the-shelf anti-BCMA CAR-T cell therapy to a 60% response rate in a phase 1 trial

79. (Merkel cell carcinoma, NCI Thesaurus) A drug used together with UV light to treat psoriasis, vitiligo, and skin nodules of Cutaneous T-cell lymphoma

80. City of Hope's Behnam Badie, M.D., is a renowned neurosurgeon and expert in the field of surgical neuro-oncology, nanotechnology and T cell research.